ACOTEC
先瑞达

Acotec Scientific Holdings Limited

2024H1 Business Performance Review

Sep. 2024

TRUSTED INNOVATION
FOR LIFE

ACOTEC
先瑞达

Legal Disclaimer

- This Presentation is strictly confidential and subject to the terms and conditions described below. It is only sent to some people and provided with information about Acotec Scientific Holdings Limited (the "Company") to help you decide whether to conduct in-depth research on the Company. The information contained in this Presentation has not been verified by any regulatory agency in any jurisdiction. The content of this Presentation (regardless of all or part of the content and regardless of the purpose) shall not be copied, distributed or shared directly or indirectly with any person (regardless of whether such person is a member of your company or group). In particular, neither the information contained in this Presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong, Singapore or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. Anyone who obtains this Presentation should understand or be familiar with such restrictions.
- This Presentation and the information contained therein have not been independently verified and are not intended to constitute the basis for making investment decisions. The content of this Presentation does not constitute or form and shall not be construed as a solicitation of an offer for the sale or purchase of securities under any other jurisdiction. Any part of this Presentation does not constitute the basis of any contract or undertaking. Any decision to purchase the Company's securities in a public or private offering shall be based on the prospectus or international offering circular prepared by the Company for the relevant securities offering and any supplementary price information. This Presentation does not include any information or materials that would cause this Presentation to constitute(i) a prospectus under Section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) (Cap.32 of Hong Kong) or the Securities Act of 1933 (as amended) (the “Securities Act"), or an advertisement in relation to a prospectus or proposed prospectus, or an extract from or abridged version of a prospectus under Section 38B of the Companies (Winding-up and Miscellaneous Provisions), or an advertisement, invitation or document which contains any advertisement or invitation under Section 103 of the Securities and Futures Ordinance (Cap. 571 of Hong Kong), or (ii) an invitation to the public made in Hong Kong without abiding by Hong Kong law or introducing exemptions under Hong Kong law. This Presentation is subject to change without notice.
- The Company’s securities have not been and will not be registered under the Securities Act or the securities law of any state in the United States, and may not be offered or sold in the United States without registration or obtaining relevant applicable exemptions. Neither this Presentation nor its content constitutes or forms, and shall not be construed as part of an offer or solicitation of an offer to subscribe for securities in the United States. The Presentation shall not be carried or transmitted to the United States (including its territories and commonwealths, any state or the District of Columbia), or distributed directly or indirectly in the United States (including its territories and commonwealths, any state or District of Columbia). The Company's securities will not be offered or sold in the United States except for transactions that are not subject to exemptions under the provisions of the Securities Act or not subject to the Securities Act.
- By participating in or by reading this Presentation, you are recognized to have made representations and warranties to the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you and any you represent (if any) are either (i) a “qualified institutional buyer” (within the meaning of Rule 144A under the United States Securities Act of 1933, as amended), or (ii) outside the United States.. You are also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.
- The information in this Presentation is provided by the Company. This Presentation is not intended to be comprehensive or to contain all the information you may need to evaluate the Company. Regarding the accuracy, reliability, correctness, reasonableness, fairness or completeness of this Presentation or any information therein, or any oral or written communication regarding the evaluation of the Company, none of the parties (to avoid ambiguity, including but not limited to the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors) has or will make any express or implied statement or guarantee, and shall not, within the scope permitted by law, assume any liability arising therefrom. In particular, regarding the realization or reasonableness of any assumptions, speculations, goals, estimates or prospects contained in this Presentation, no express or implied statements or guarantees are made, nor should you rely thereon. Some of the information contained herein comes from different sources, including some third parties, and has not been independently verified by the Company. For the losses caused to you or any person using or relying on the information contained or disclosed in this Presentation, the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents or representatives shall take no responsibility (whether in negligence or otherwise). The use of registered trademarks, commercial trademarks and logos or photographic materials within this Presentation are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.
- This Presentation is subject to the disclaimer and restrictive language contained therein. Any person shall make their independent evaluation and analysis, and shall not use any information mentioned, discussed or quoted in therein as the basis for their actions. You understand and assure the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you are a professional investor and have the knowledge, experience and ability required to evaluate the Company, you will make independent evaluation of the Company, its securities and all the information provided, and you have or will obtain independent advice for the evaluation of the Company’s securities.
- This Presentation may contain the Company’s current beliefs and expectations regarding the indicated future dates. Such forward-looking statements are based on some assumptions about the Company’s operations or factors outside the Company’s control, and may be affected by a number of known and unknown factors. Therefore, the Company’s actual performance may be materially different from these forward-looking statements. You shall not rely on such forward-looking statements. The Company, the parties involved in the issuance of the Company’s securities, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors shall not be obliged to update or revise such forward-looking statements in response to new information, events or circumstances that occur after these dates.
- This Presentation and the information contained therein are strictly confidential. This Presentation and the information contained therein shall not be copied, reproduced, or transmitted to others in any form, or disclosed for any purpose (whether in whole or in part). Failure to comply with these restrictions may constitute a violation of the law and may result in legal or regulatory action. By receiving this Presentation or the information therein, you agree (1) that you have read and agree to abide by the requirements in this disclaimer; and (2) that you will keep the information contained in this Presentation strictly confidential.
- By participating in and accepting this Presentation, you agree to maintain the absolute confidentiality of the information contained in this Presentation and accept the restrictions and other conditions stated therein. Failure to comply with these restrictions and conditions may violate relevant laws and regulations and result in legal or regulatory measures.

ACOTEC
先瑞达

01 2024H1 Financial Performance Review

02 The Progress of CCT Implementation

03 Product Commercialization

04 R&D and Product Approvals

TRUSTED INNOVATION
FOR LIFE

AGOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

01

2024H1 Financial Performance Review

2024H1 Financial Performance Review (1/3)

TRUSTED INNOVATION
FOR LIFE

The business sustained rapid growth while achieving a more diversified income



- Acotec achieved a revenue of **RMB 292mn** in 2024H1, showing robust growth with a **20% increase** over 2023H1.
- SFA DCB revenue amounted to RMB 142mn, while BTK DCB revenue saw a period-on-period growth of over **20% at RMB 32mn**.
- Revenue from **Venous Intervention, vascular access, and other products** reached **RMB 118mn**, marking a **period-on-period growth of over 30% and contributing 40% of total revenue**, serving as a significant driver for the company's business expansion.
- Overseas product sales achieved revenue of approximately 12mn with a period-on-period i**ncrease of 96%,** and the proportion of overseas income further expanded to 4.1%.

Gross Profit & Gross Profit Margin



- Acotec attained a **gross profit of RMB 217mn in 2024H1**, with **a gross profit margin** of approximately **74.3%**. The slight decrease in gross profit margin were mainly due to: 1) The revenue contribution from venous products is rapidly increasing, and its proportion in total revenue is climbing, although the margin of these products is lower than that of DCBs; 2) The overseas sales of DCB products are growing rapidly, but the gross margin from these sales is lower than that from domestic sales; 3) The sales price dropped due to VBP in certain areas.

2024H1 Financial Performance Review (2/3)

TRUSTED INNOVATION
FOR LIFE

R&D expenses



- In 2024H1, the R&D expenses were about **100mn**, up 11.8% period-on-period. This increase is due to both the addition of **new projects and the expansion of the R&D team, as well as higher costs as key projects progress.**
- The R&D expense ratio has been optimized to 34%, reflecting the company's revenue growth, effective cost management, and better economies of scale.

Selling and distribution expenses



- In 2024H1, sales expenses were approximately **50mn**, a 10% increase period-on-period, mainly due to **increased market and academic activities** aimed at enhancing physician and patient education and strengthen brand influence, thereby **maintaining a competitive edge**.
- The sales expense ratio decreased to 17%.

Administrative expenses



- In 2024H1, the company's operational improvements resulted in an **11.8% decrease in administrative expenses**, with the expense ratio falling to 11.6%. This reduction was primarily due to the elimination of consulting fees and the transfer of depreciation and amortization costs from administrative to production and R&D expenses following the completion of factory construction.

2024H1 Financial Performance Review (3/3)

TRUSTED INNOVATION
FOR LIFE

Profit from operations & Net Profit

(In millions RMB)



- In 2024H1, we achieved an **operating profit of 46.2 million**, marking a 69.1% increase from 2023H1. The operating profit directly reflects our enhanced profitability and effective cost management.
- The company reported a net profit of **39.95mn, up 78.6% period-on-period**. With a robust and sustainable self-funding ability, the ongoing inflow of operating cash has optimized our asset structure, enabling further investment in R&D and commercial activities.

Liquidity and Financial Resources

(In millions RMB)



- At the end of 2024H1, the Company had a total of 930mn in financial resources available, an **increase of about 5.8%** from the end of the previous period (December 31, 2023), which was 879mn. This growth was **mainly due to cash inflows from the company's operating activities.**
- The ample financial reserves on hand ensure the company's continued stable operation and support ongoing exploration of business development opportunities.

AGOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

02

The Progress of CCT Implementation

Key Updates on Collaboration with BSC (1/2)

TRUSTED INNOVATION
FOR LIFE

Commercialization Collaboration Progress

Overseas Market

- **Distribution Agreement signed** for **SFA & BTK DCB sales in overseas market in 2023.**
- BSC has commenced selling Acotec products in overseas market.

Chinese Market

- **Distribution Agreement signed** for Approved **Coronary Products**(YAN, RT-Zero® and Vericor-14®), **AVF Products** (AcoArt Orchid® (AVF indication), AcoArt Iris® (AVF indication) and ACOART AVENS®) in 2023 and distribution agreement signed for AV Scoring Balloon (Peridge®) in 2024. BSC has commenced selling Acotec products.
- **The collaboration scope will broaden** with the expected approval of several new products in 2024.

Global Expansion landscape of Collaborative Products

With the launch of additional products in China and globally, the scope and geographical coverage of collaboration are continuing to expand.

Overseas countries

SFA DCB
AcoArt Orchid®

BTK DCB
AcoArt Tulip® & Litos®

SFA DCB and BTK DCB have further expanded their coverage in overseas countries in 2024:

- Finland
- Sweden
- Austria
- Chile
- The United Kingdom
- The Netherlands

China

PTCA Balloon YAN

Micro-catheter Vericor-14®

CTO small Balloon RT-Zero®

AcoArt Orchid® (AVF indication)

PTA Balloon AcoArt Iris® (AVF indication)

AVF DCB ACOART AVENS®

AV Scoring Balloon Peridge®

Key Updates on Collaboration with BSC (2/2)

TRUSTED INNOVATION
FOR LIFE

Internal Process Alignment and Qualification Completed in 2023

- **Qualified Supplier**
- **Supply Chain Integration**

- Acotec is **accelerating the overseas product registration process** to meet the increasing sales demands of BSC.

More countries,
More products...



Estimated Revenue from Collaboration in 2024

¥37.5 Million

1. FX: 7.1074
2. The estimated revenue for collaborative products includes signed contracts.

03

Product Commercialization

We maintained market competitiveness through our reliable products and first-mover advantages

TRUSTED INNOVATION
FOR LIFE

SFA DCB
AcoArt Orchid® & Dhalia®/ Orchid Plus

1700
Hospital Admitted

- Acotec's SFA DCB is the first approved product in China. With early-mover advantage and outstanding clinical performance, we have established a strong competitive edge;
- Still the leading brand in market share.

冀 HEBEI

- Winning bids in Hebei+ Sanming VBP;
- We saw a rapid increase in hospital admissions and implantations in the VBP areas.

BTK DCB
AcoArt Tulip® & Litos®

800
Hospital Admitted

- Exclusive products in China;
- We are committed to improving physicians' therapeutic approaches and skills.

Acotec@VEC2024

Acotec@SJVF2024

BTK Surgery Demonstration

BTK DCB-China Real World Data Release @LINC



We maintained market competitiveness through our reliable products and first-mover advantages

TRUSTED INNOVATION
FOR LIFE

Peripheral Aspiration System AcoStream®

1560

Hospital Admitted

- 2 generations of products consolidate our market competitiveness;
- Huge and Urgent demand in lower-tier markets;
- A vital growth driver for the company.

豫 HENAN

- Winning the bid in Henan's VBP has accelerated product admissions in hospitals and increased implanting volumes.

RFA System AcoArt Cedar®

500

Hospital Admitted

- Continuously expanding hospital coverage, conducting training programs to enhance doctors' skills and knowledge, promoting therapy transformations.

豫 HENAN

- Winning the bid in Henan's VBP has accelerated product admissions in hospitals and increased implanting volumes.

AcoStream Thrombectomy Case Competition

Sharing of Standard Operations for AcoStream


AcoStream在DVT腔内祛栓中的细节优化管理及规范化操作浅谈（上篇）

北京先瑞达 北京先瑞达 2024年06月21日 11:31 上海

2024年5月25日在第十三届上海交通大学血管病论坛学术交流上，来自宁波市第二医院余钻标教授分享他在临床中应用AcoStream吸栓导管治疗下肢深静脉血栓形成的一些见解，并进一步总结了在AcoStream导管进行腔内祛栓中的细节优化管理及规范化操作，以进一步提高吸栓效率及吸栓安全性。

本期推送将带来AcoStream在DVT腔内抽吸血栓时需做好的八大点细节优化管理上篇（即1-4点），后续内容将在下篇中呈现，敬请期待。

RFA System Experience Sharing Seminar

Varicose Vein- Free Medical Consultation

A Review on the Company's Product Winning Bids in VBP

TRUSTED INNOVATION
FOR LIFE

	FEB	MAR	APR	MAY	JUN	JUL	AUG-DEC	JAN	FEB	MAR	APR	MAY	JUN
HENAN VBP	Release Notification						Being Implemented in Henan Province					Continuation Purchase Notice	
HEBEI+ SANMING VBP		Release Notification					Gradually being Implemented in Hebei Province and other Sanming Alliance provinces and cities						
JJJ "3+N" VBP							Release Notification						Being Implemented

HENAN VBP ✓

Aspiration System

RFA System

PTA Balloon

- VBP was being conducted for neuro intervention and peripheral intervention products, covering public hospitals within Henan Province.
- **Aspiration System, RFA System and PTA Balloon have been successfully awarded contracts.**

HEBEI+ SANMING VBP ✓

SFA DCB

Other products of our company have not been included in this VBP

- A VBP for 19 types of products including biopsy needles and contrast catheters has been conducted, with peripheral DCB included in the scope. The coverage area includes Hebei Province and other provinces and cities within the Sanming Alliance.
- Acotec's SFA DCB have been successfully awarded contracts in both ≤150mm and >150mm specifications, with rapid growth in implant volume within the VBP areas after implementing.

JJJ (京津冀) "3+N"

- The procurement category did not include the company's peripheral interventional products that were already launching in the market.

- ✓ **Embracing the opportunities brought by VBP**
- ✓ **Solidifying our leading position in the existing market and actively seize new market opportunities**
- ✓ **With rapid growth in implant volume and a steady increase in market supply, the industry is set to enter a period of accelerated development.**

04

R&D and Product Approvals

We've proactively positioned several innovative products, with 2024 is anticipated to be a bumper year for product approvals.

TRUSTED INNOVATION
FOR LIFE

3 New Approvals(2024/6/30)

Nephrology

Cardiology



Cardiology

6 Products have been applied for registration with the NMPA



Intracranial DCB
AcoArt Daisy®

- Vertebral Artery DCB
- Coronary Paclitaxel DCB
- Coronary Sirolimus DCB
- Peripheral Coil
- Peripheral Scoring Balloon

Multiple products are undergoing clinical trials

BTK DCB (U.S.)

Peripheral Sirolimus DCB



Peripheral Spot Stent

Peripheral IVL System

.....

We have developed a product pipeline that spans multiple departments, creating a competitive edge with a comprehensive product portfolio.

TRUSTED INNOVATION
FOR LIFE

17 Approved Products

11 Products under development/registration/clinical trials

1 DCB indication expansion

21 Overseas countries converge

Vascular Surgery

9 + 6

Vascular Access	Vascular Preparation	Vascular Treatment
Support Catheter	PTA Balloon (SFA)	SFA DCB
	PTA Balloon (BTK)	BTK DCB
	Tapered PTA Balloon	
	Peripheral Scoring Balloon	Peripheral Sirolimus DCB
	Peripheral IVL System	Peripheral Spot Stent

Peripheral Arterial Atherosclerotic Stenosis

Arterial Aneurysm

- Peripheral Coil
- .....

Venous thromboembolism

Aspiration System

2nd Gen Aspiration System

varicose veins

RFA System

Cardiology

5 + 3

Coronary Artery Calcification and CTO lesions	Coronary Artery Stenosis
Coronary CTO Recanalization Balloon	Semi-compliant PTCA Balloon
Coronary CTO Antegrade Micro-Catheter	Coronary High-Pressure PTCA Balloon
Coronary CTO Retrograde Micro-Catheter	Coronary Paclitaxel DCB
Coronary IVL System	Coronary Sirolimus DCB

Nephrology

2 + 1

AVF Stenosis

- Paclitaxel Coated High-pressure Balloon
- SFA DCB (AVF indication)
- AV Scoring Balloon

Neurology

1 + 2

ICAS	VAO Stenosis
Intracranial PTA Balloon	Vertebral Artery DCB
Intracranial DCB	

Approved | Under development/registration/clinical trials | DCB Indication Expansion

We have launched several first & best-in-class products, and the approval process is accelerating both in domestic and international market

TRUSTED INNOVATION
FOR LIFE

2016-2021

5

Key Products

- SFA DCB
- BTK DCB
- Aspiration System

2022

5 + 1

Key Products

- RFA System
- SFA DCB (AVF indication expansion)
- Peripheral Support Catheter

2023

4

Key Products

- Aspiration System(2nd Gen)
- AVF DCB
- BTK DCB
- FDA IDE Approval

2024

3 + 6

Key Products



- Intracranial DCB
- Vertebral Artery DCB
- Coronary Sirolimus DCB
- Coronary Paclitaxel DCB

2025-2026

5

Key Products


- Peripheral Sirolimus DCB
- Peripheral Spot Stent
- IVL System
- .....

Approved

Under development/registration/ clinical trials

DCB Indication Expansion

The First Approved Product in China

The First Approved Domestically Manufactured Product in China

Acotec Intracranial DCB, AcoArt Daisy®, achieves excellent clinical trial results

TRUSTED INNOVATION
FOR LIFE

Clinical Trial



The restenosis rate at 6-month follow-up



Superior efficacy clinical trial results

The target lesion restenosis rate at 6-month

	DCB Group	Stent Group	Rate difference and 95% CI
Number of Follow-up Cases	73	76	NA
Number of Cases with Lesion Restenosis	5	25	NA
Restenosis Rate	6.85% (5/73)	32.89% (25/76)	-19.02% (-27.42, -6.18%)

Forecasted volume of ICAS interventional procedures

- With a recorded 5mn stroke cases in 2019, including around 3.5mn ischemic strokes, approximately 1.6mn cases involved ICAS.
- Considering the rising patient awareness and the advancing maturity of intracranial vascular disease intervention, the projected volume of interventional surgeries is expected to **reach 287.3 thousand per year by 2030.**

Market size forecast for DCB in treating ICAS



- Based on data analysis, after the approval and introduction of Acotec intracranial DCB, the market size for intracranial DCB (ICAS indication) is forecasted to reach approximately **RMB 837.8mn by 2030**.

Data sources: Anand Alurkar et al.; Stroke. 2013; 44:2000-2003; Jiang Weijiang et al.; Multicenter analysis of symptomatic intracranial atherosclerotic stenting; Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis - Chinese Expert Consensus (2018); Drug-Coated Balloon for Treatment of Symptomatic Intracranial Atherosclerosis: Initial Experience and Follow-Up Results; Neuro Elutax SV Drug-Eluting Balloon vs. Wingspan Stent System in Symptomatic Intracranial High-Grade Stenosis: Single-Center Experience; DOI: 10.3969/j.issn.1673-5765.2018.06.012; Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis - Chinese Expert Consensus (2018); WANG YJ, ZHAO XO, LIU LP et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) study [J]. Stroke, 2014, 45(3): 663-669.; Frost Sullivan Analysis.

The vertebral artery DCB has shown excellent clinical trial results, and its launch will further strengthen the company's position in the neurointerventional field.

TRUSTED INNOVATION FOR LIFE

Clinical Trial

Treatment Group
AcoArt Verbena®
& Vinca® DCB



Control Group
Apollo® Stent



Study Objective	To verify the efficacy and safety of Vertebral DCB in the endovascular treatment of vertebral artery origin (VAO) stenosis
Study Design	Prospective, multicenter, randomized controlled non-inferiority trial
Patients Enrollment	180 patients 1:1 allocate to the DCB group and the Stent group.
Primary Study Endpoints	12-month follow-up: Restenosis rate of the target lesion

The restenosis rate at 12-month follow-up



Superior efficacy clinical trial results

	DCB Group	Stent Group	Rate difference and 95% CI
Number of Follow-up Cases	69	67	NA
Number of Cases with Lesion Restenosis	9	25	NA
Restenosis Rate	13.04%	37.31%	-24.27% (-38.31%, -10.23%)

VAO stenosis is a significant factor in ischemic stroke occurrence

Ischemic strokes account for **70.2%** of all strokes



25%~40% of ischemic strokes occur in the posterior circulation

- Stroke is the second leading cause of death and the third leading cause of disability globally.
- 25-40% of ischemic strokes occur in the posterior circulation, with 9-33% having VAO stenosis or occlusion.
- **Treating VAO stenosis is significant for stroke prevention.**

Source: Frost & Sullivan research report; CIC research report.

The market for DCB treatment of vertebral artery stenosis holds promising prospects

2030E

216.2 thousand

- Traditional stent/balloon angioplasty may lead to neointimal hyperplasia and relatively high rates of restenosis. DCB treatment has the advantages of no implants left in the blood vessels, offers promising prospects for future treatments.
- According to CIC Consulting research, it is projected that by 2030, the number of surgeries for ischemic stroke treated with DCB will be approximately 216,000.

A series of significant coronary products are on the verge of regulatory approval, creating a robust basis for market expansion—Coronary DCBs

TRUSTED INNOVATION
FOR LIFE

Clinical Trial- Coronary Sirolimus DCB

Treatment Group Acotec-Coronary Sirolimus DCB	Control Group Yinyi-Bingo Paclitaxel DCB

Study Objective	To verify the efficacy and safety of Coronary Sirolimus DCB in the treatment **of bifurcation lesions** in coronary arteries
Study Design	Prospective, multicenter, randomized controlled non-inferiority trial
Patients Enrollment	230 patients 1:1 allocate to the Treatment group and the Control group
Primary Study Endpoints	At 9 months post-surgery, the diameter stenosis rate (DS.%) of the target lesion branch vessel as shown by angiography.

	Treatment Group	Control Group	Rate difference and 95% CI
Number of cases included in the PPS	91	94	-
The diameter stenosis rate of the target lesion	30.52%	33.46%	-1.93% (-5.79%, 1.92%)

✓ **The non-inferiority hypothesis is established**

Clinical Trial- Coronary Paclitaxel DCB

Treatment Group Acotec-Coronary Paclitaxel DCB	Control Group Cardionovum-RESTORE DEB

Study Objective	To verify the efficacy and safety of Coronary Paclitaxel DCB in the treatment of **small vessel disease** in coronary arteries
Study Design	Prospective, multicenter, randomized controlled non-inferiority trial
Patients Enrollment	230 patients 1:1 allocate to the Treatment group and the Control group
Primary Study Endpoints	At 9 months post-surgery, the intra-segment diameter stenosis rate (DS.%) as shown by angiography

	Treatment Group	Control Group	Rate difference and 95% CI
Number of cases included in the PPS	96	98	-
The intra-segment diameter stenosis rate	31.09%	40.32%	-9.16% (-13.99%, -4.34%)

✓ **On the basis of the non-inferiority hypothesis, superior efficacy results are achieved**

Both products have submitted registration applications and are expected to be approved for marketing by the end of 2024

We have expanded our manufacturing capabilities in the upstream of the industry chain and create a competitive edge in R&D and production

TRUSTED INNOVATION
FOR LIFE



Hydrophilic Lubricious Coatings

- We have gradually mastered advanced hydrophilic lubricating coating technology, which has superior performance to international products. This will enhance our product performance, significantly reduce raw material costs, and shorten the overseas procurement cycle.

Enhancing R&D Efficiency
We utilize our in-house technology to expedite prototyping. This allows for more trial-and-error opportunities, enhancing R&D efficiency while maintaining quality.

Self-sufficiency in producing raw materials
Our self-produced raw materials have achieved the desired quality level, and we are gradually replacing some of the originally imported materials with our own.

Reduce R&D and production costs
The efficient R&D, as well as a high proportion of self-produced raw materials, have helped us achieve cost reduction and efficiency improvement.



Laser Cutting

Laser Welding

Extrusion & Balloon Forming



Coiling



Catheter Assembly



Braiding

We are enhancing manufacturing capacity in Beijing & Shenzhen to meet increasing market demand

TRUSTED INNOVATION
FOR LIFE

2+M Units/Year

One-shift Production Capacity, can double by working in two shifts
(After Beijing & Shenzhen New Facility fully put in use)

1+M Units/Year

Production Capacity for OEM, can double by working in two shifts
(After Beijing & Shenzhen New Facility fully put in use)

The gross floor area of production facilities	
30,800m²	6,220m²
Beijing	Shenzhen

Production Capacity		
466,644	202,811	43.5%
Production Capacity	Actual Production Volume	Utilization Rate

Beijing Manufacturing Facility


Shenzhen Manufacturing Facility



New Beijing Facility

AGOTEC
先瑞达

THANKS!

谢谢！

TRUSTED INNOVATION
FOR LIFE

Appendix: Products and Pipeline-Full Product Portfolio (1/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Vascular Surgery	AcoArt Orchid® & Dhalia®/Orchid Plus★ Note 1	Superficial femoral artery (SFA) and popliteal artery (PPA) disease	Drug coating technology	China	✓	✓	NMPA Approval★	/
				EU	✓	✓	CE★	/
	AcoArt Tulip®& Litos®★	Below-the-knee (BTK) artery disease	Drug coating technology	China	✓	✓	NMPA Approval★	/
				EU	✓	✓	CE★	/
				U.S.	✓	FDA IDE Approval		
	AcoArt Iris® & Jasmin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	NMPA Approval★	/
	AcoArt Lily® & Rosmarin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	NMPA Approval★	/
	Peripheral Aspiration System (AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓	Exempted from clinical trial	NMPA Approval★	/
				Brazil	✓		ANVISA Approval★	/
	Radiofrequency Ablation System (AcoArt Cedar®)	Saphenous varicose veins	RF platform	China	✓	✓	NMPA Approval★	/
	Peripheral Support Catheter (Vericor®)▲	Peripheral CTO lesion	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
				U.S.	✓		FDA Approval★	/
				Brazil	✓		ANVISA Approval★	/
				Thailand	✓		TFDA Approval★	/
				Japan	✓		MHLW Approval★	/
	PTA Balloon (P-Conic®)	PTA	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
	2nd Gen Peripheral Aspiration System (2nd Generation AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓	Exempted from clinical trial	NMPA Approval★	/
	Peripheral Spot Stent	SFA and PPA disease	Polymer materials	China	✓			2026
	Lower Limb Sirolimus DCB	SFA and PPA disease	Drug coating technology	China	✓			2026
	Peripheral Scoring Balloon	SFA and PPA disease	Polymer materials	China	✓	✓		2024
	Peripheral Coil	Embolization	Polymer materials	China	✓	✓		2024
	Peripheral Thrombectomy Device	DVT, ALI and PE	Polymer materials	China				2025
	Peripheral IVL System	Intravascular calcium	Polymer materials	China	✓			2026

★Core product ☆ Indication expansion of core product ★Commercialization

▲ Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (《免於進行臨床試驗醫療器械目錄》) promulgated by the NMPA, as amended.

Note: We have been continuously improving the performance of AcoArt Orchid® & Dhalia™. As advised by NMPA and as part of our business strategy, we decided not to register Orchid Plus as a separate product. Alternatively, we applied to register Orchid Plus as an upgrade version of AcoArt Orchid® & Dhalia® with improved delivery balloon catheter system, and received the revised NMPA approval for AcoArt Orchid®& Dhalia® in November 2021.

Appendix: Products and Pipeline-Full Product Portfolio (2/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Cardiology	Semi-compliant PTCA Balloon (YAN)	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Recanalization Balloon (RT-Zero®)▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Antegrade Micro-Catheter (Vericor-14®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
				Japan			MHLW Approval★	/
				Thailand			TFDA Approval★	/
	Coronary Retrograde Micro-Catheter (Vericor-RS®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	Coronary High-Pressure Balloon (YIYAN)	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	AcoArt Camellia® (DCB)	Coronary small vessel diseases	Drug coating technology	China				2024
	Coronary Sirolimus DCB	Bifurcation lesions	Drug coating technology	China				2024
	Coronary IVL System	Coronary lesion calcium	Polymer materials	China				2026
Nephrology	AcoArt Orchid®& Dhalia®/Orchid Plus☆(DCB)	Arteriovenous fistula stenosis	Drug coating technology	China			NMPA Approval★	/
	Paclitaxel Coated High-pressure Balloon ACOART AVENS®▲	AVF PTA procedure	Drug coating technology	China			NMPA Approval★	/
	AV Scoring Balloon (Peridge®) Note 2	AVF PTA procedure	Polymer materials	China			NMPA Approval★	/
Neurology	Intracranial PTA Balloon (NEO-Skater®)▲	Intracranial PTA procedure	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	AcoArt Verbena®& Vinca® (DCB)	Vertebral atherosclerotic stenosis	Drug coating technology	China				2024
	AcoArt Daisy®	Intracranial atherosclerotic stenosis	Drug coating technology	China				2024

★Core product ☆ Indication expansion of core product ★Commercialization